|
gptkbp:instance_of
|
gptkb:monoclonal_antibody
|
|
gptkbp:bfsLayer
|
4
|
|
gptkbp:bfsParent
|
gptkb:Saphnelo
|
|
gptkbp:activities
|
inhibits type I interferon signaling
|
|
gptkbp:approves
|
gptkb:2021
gptkb:FDA
|
|
gptkbp:brand
|
gptkb:Saphnelo
|
|
gptkbp:clinical_trial
|
Phase III
treatment of lupus
NC T02446899
NC T03021499
NC T03328990
|
|
gptkbp:contraindication
|
active infections
severe hepatic impairment
hypersensitivity to anifrolumab
|
|
gptkbp:developed_by
|
gptkb:temple
|
|
gptkbp:dosage_form
|
solution for infusion
|
|
gptkbp:exemplifies
|
sodium citrate
sodium chloride
water for injection
|
|
gptkbp:financial_performance
|
24 months at -20° C
|
|
gptkbp:formulation
|
sterile solution
|
|
gptkbp:frequency
|
every 4 weeks
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
anifrolumab
|
|
gptkbp:indication
|
autoimmune diseases
|
|
gptkbp:ingredients
|
C6480 H10080 N1716 O2016 S44
|
|
gptkbp:interacts_with
|
immunosuppressants
live vaccines
other biologics
|
|
gptkbp:invention
|
patented
|
|
gptkbp:is_effective_against
|
improves quality of life
decreases corticosteroid use
reduces disease activity
|
|
gptkbp:is_monitored_by
|
infections
liver function tests
blood counts
|
|
gptkbp:is_tested_for
|
Phase II
Phase III
|
|
gptkbp:is_used_for
|
gptkb:systemic_lupus_erythematosus
|
|
gptkbp:manager
|
intravenous
IV infusion
|
|
gptkbp:marketed_as
|
gptkb:legislation
gptkb:United_States
|
|
gptkbp:population
|
adults with moderate to severe lupus
|
|
gptkbp:produced_by
|
marketed
|
|
gptkbp:provides_information_on
|
gptkb:ACR_guidelines_for_lupus
|
|
gptkbp:research_areas
|
immunology
|
|
gptkbp:safety_features
|
generally well tolerated
|
|
gptkbp:side_effect
|
fatigue
headache
nausea
infections
infusion reactions
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:targets
|
gptkb:healthcare_organization
interferon receptor
|
|
gptkbp:weight
|
146 k Da
|